E25Bio develops Rapid Diagnostic Tests for fever syndromes which account for over 1 billion episodes annually and are one of the most common reasons to seek care worldwide . The company is working on rapid diagnosis of diseases such as dengue, zika and COVID-19. E25VBio’s diagnostic tests use nanoparticle technology to capture virus or viral proteins that are secreted in the body based on technology developed by Irene Bosch and Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology at MIT.
The company’s COVID-19 test is similar to a pregnancy test and it has received $2 million from Khosla Ventures which will fund research and development, clinical studies and scaling launch of diagnostic tests once FDA Emergency Use Approval (EUA) approval is received.
Bobby Brooke Herrera
A comparison of nanoparticle-antibody conjugation strategies in sandwich immunoassays. - PubMed - NCBI
pubmeddev, Tam JO , et al.
Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. - PubMed - NCBI
pubmeddev, Bosch I , et al.
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.